

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

方舟健客

Fangzhou Inc.

方舟云康控股有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock code: 6086)

APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Fangzhou Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. WANG Haijiao (王海蛟) (“**Mr. Wang**”) has been appointed as the chief executive officer of the Company (the “**CEO**”) and an executive Director with effect from March 26, 2026.

The biographical details of Mr. Wang are set out below:

Mr. Wang, aged 45, was previously the deputy general manager, investment committee member, and an executive partner of GTJA Investment Group, which he joined in 2014. He possesses nearly 20 years of experience in entrepreneurship, management, and investment within the healthcare industry, with a particular focus on in vitro diagnostics (IVD), precision medicine, and digital health. Prior to joining GTJA Investment Group, Mr. Wang served as an investment director at Dragon Rise Capital from 2012 to 2014. Mr. Wang also currently serves as a director of Guangzhou LBP Medicine Science & Technology Co., Ltd. (Stock Code: 688393.SH).

Mr. Wang received a master’s degree in microbiology from the School of Life Sciences at Fudan University (復旦大學) in 2006. He obtained a master’s degree in business administration (MBA) from the School of Management at Fudan University in 2013, and an executive master’s degree in business administration (EMBA) from the Shanghai Advanced Institute of Finance at Shanghai Jiao Tong University (上海交通大學) in 2021.

Mr. Wang has entered into a service contract with the Company for a term of three years for his role as the CEO and an executive Director with effect from the date of his appointment. Under the terms of his appointment, Mr. Wang is entitled to a base salary of RMB 2,400,000 per annum. The remuneration package of Mr. Wang was determined by the Board with reference to his duties and responsibilities, the Company's remuneration policy, and prevailing market conditions, upon the recommendation of the remuneration committee of the Company. In accordance with the articles of association of the Company, Mr. Wang will hold the office of executive Director only until the next following annual general meeting of the Company and shall be eligible for re-election at that meeting. As an executive Director, he is subject to retirement by rotation and re-election at the annual general meetings of the Company at least once every three years in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

As at the date of this announcement, save as disclosed above, Mr. Wang (i) does not hold any other positions with the Company or other members of the Group; (ii) has not held any other directorships in the last three years in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Wang that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited, and there is no information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Mr. Wang to his new role as the CEO and an executive Director.

By order of the Board

Fangzhou Inc.

ZOU Yuming

Executive Director and Joint Company Secretary

Hong Kong, March 26, 2026

As of the date of this announcement, the Board comprises Mr. ZHOU Feng, Mr. ZOU Yuming and Mr. WANG Haijiao as executive Directors, Mr. David McKee HAND and Mr. XIE Fangmin as non-executive Directors, and Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu as independent non-executive Directors.